Cost-effectiveness of robotic surgery compared to conventional laparoscopy for the management of early-stage cervical cancer: a model-based economic evaluation in China

被引:0
|
作者
Chen, Chunlan [1 ]
Zhang, Min [1 ]
Tang, Junying [2 ]
Pu, Kexue [1 ]
机构
[1] Chongqing Med Univ, Sch Med Informat, Chongqing, Peoples R China
[2] Chongqing Med Univ, Affiliated Hosp 1, Dept Gynecol, Chongqing, Peoples R China
来源
BMJ OPEN | 2024年 / 14卷 / 11期
基金
中国国家自然科学基金;
关键词
China; Health economics; Minimally invasive surgery; Gynaecological oncology; RADICAL HYSTERECTOMY; ENDOMETRIAL CANCER; ASSISTED LAPAROSCOPY; SINGLE SURGEON; OUTCOMES; MORBIDITY;
D O I
10.1136/bmjopen-2024-087113
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The aim of this study is to assess cost-effectiveness of robotic radical hysterectomy (RRH) vs laparoscopic radical hysterectomy (LRH) in early-stage cervical cancer (ECC).Design Model-based cost-effectiveness analysis.Setting Based on long-term survival data, a three-state Markov model was constructed using TreeAge Pro 2022 to simulate the possible recurrence of ECC. Data on clinical efficacy and costs were derived from published literature and local databases.Participants A hypothetical cohort of 1000 individuals diagnosed with early-stage cervical cancer (FIGO 2009 stages<IIB) who underwent RRH or LRH management.Outcome measures The study endpoints were quality-adjusted life years (QALYs), total costs (in Chinese renminbi (RMB) adjusted to 2023-year values using the Consumer Price Index) and incremental cost-effectiveness ratio (ICER). A willingness-to-pay threshold of 268 074 RMB per QALY was used to assess cost-effectiveness.Results Robotic group gained more 4.84 QALYs than the laparoscopic group, but total costs for robotic strategy are substantially higher, with the incremental costs of 1 031 108 RMB. The ICER of robotic strategy is 213 054 RMB per QALY. Outcomes were robust in most one-way sensitivity and probabilistic sensitivity analyses.Conclusions Robotic strategy is on the efficient frontier but incurs substantial initial cost. Our findings indicated that this strategy is a cost-effective treatment option for ECC patients if assessed over a time horizon of patients' lifetime. This study underscores the need for long-term clinical trials in early-stage cervical cancer patients with follow-up data that capture financial and quality-of-life end points.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Cost-effectiveness of adalimumab for early-stage Dupuytren's disease AN ECONOMIC EVALUATION BASED ON A RANDOMIZED CONTROLLED TRIAL AND INDIVIDUAL-PATIENT SIMULATION MODEL
    Dakin, H.
    Rombach, I.
    Dritsaki, M.
    Gray, A.
    Ball, C.
    Lamb, S. E.
    Nanchahal, J.
    BONE & JOINT OPEN, 2022, 3 (11): : 898 - 906
  • [22] Model-Based Impact and Cost-Effectiveness of Cervical Cancer Prevention in Sub-Saharan Africa
    Kim, Jane J.
    Campos, Nicole G.
    O'Shea, Meredith
    Diaz, Mireia
    Mutyaba, Innocent
    VACCINE, 2013, 31 : F60 - F72
  • [23] Cost-effectiveness of MR-mammography vs. conventional mammography in screening patients at intermediate risk of breast cancer - A model-based economic evaluation
    Kaiser, Clemens G.
    Dietzel, Matthias
    Vag, Tibor
    Froelich, Matthias F.
    EUROPEAN JOURNAL OF RADIOLOGY, 2021, 136
  • [24] Conservative management, surgery and radiosurgery for treatment of vestibular schwannomas: a model-based approach to cost-effectiveness
    Gait, C.
    Frew, E. J.
    Martin, T. P. C.
    Jowett, S.
    Irving, R.
    CLINICAL OTOLARYNGOLOGY, 2014, 39 (01) : 22 - 31
  • [25] MODEL-BASED EFFECTIVENESS AND COST-EFFECTIVENESS OF PERSONALIZED SELECTION STRATEGIES FOR ADJUVANT CHEMOTHERAPY IN STAGE II COLON CANCER
    Jongeneel, Gabrielle
    Greuter, Marjolein J. E.
    van Erning, Felice N.
    Koopman, Miriam
    Vink, Geraldine R.
    Punt, Cornelis J. A.
    Coupe, Veerle M. H.
    MEDICAL DECISION MAKING, 2020, 40 (01) : E80 - E81
  • [26] Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation
    Retel, Valesca P.
    Steuten, Lotte M. G.
    Foppen, Marnix H. Geukes
    Mewes, Janne C.
    Lindenberg, Melanie A.
    Haanen, John B. A. G.
    van Harten, Wim H.
    BMC CANCER, 2018, 18
  • [27] Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation
    Valesca P. Retèl
    Lotte M. G. Steuten
    Marnix H. Geukes Foppen
    Janne C. Mewes
    Melanie A. Lindenberg
    John B. A. G. Haanen
    Wim H. van Harten
    BMC Cancer, 18
  • [28] HPV16/18 vaccination to prevent cervical cancer in The Netherlands: Model-based cost-effectiveness
    Coupe, Veerle M. H.
    van Ginkel, Joost
    de Melker, Hester E.
    Snijders, Peter J. F.
    Meijer, Chris J. L. M.
    Berkhof, Johannes
    INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (04) : 970 - 978
  • [29] Cost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South Africa
    Alshreef, Abualbishr
    MacQuilkan, Kim
    Dawkins, Bryony
    Riddin, Jane
    Ward, Sue
    Meads, David
    Taylor, Matthew
    Dixon, Simon
    Culyer, Anthony J.
    Ruiz, Francis
    Chalkidou, Kalipso
    Edoka, Ijeoma
    VALUE IN HEALTH REGIONAL ISSUES, 2019, 19 : 65 - 74
  • [30] The Cost-Effectiveness of Robotic-Assisted Versus Manual Total Knee Arthroplasty: A Markov Model-Based Evaluation
    Rajan, Prashant V. V.
    Khlopas, Anton
    Klika, Alison
    Molloy, Robert
    Krebs, Viktor
    Piuzzi, Nicolas S. S.
    JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS, 2022, 30 (04) : 168 - 176